hgh

growth hormone. banned in sports, standard at every anti-aging clinic, expensive. works, with trade-offs.

tier S · growth hormone · FDA '85 Protropin · 11 labels

verdict

growth hormone. eleven FDA-approved brand labels for endocrine indications. the off-label market is everything else.

for readers researching HGH for anti-aging — Rudman's 1990 NEJM paper started the industry: twelve men over 60 with better body composition over six months. the authors never claimed anti-aging. thirty-five years later there's still no controlled trial supporting the anti-aging case in healthy adults. Liu 2007 (Annals of Internal Medicine) is the honest summary: small body-composition shifts, unclear function, common side effects (carpal tunnel, edema, glucose intolerance).

if you're asking about HGH for performance or muscle — WADA S2. 21 U.S.C. § 333(e) makes off-label distribution a federal felony in the US. the regulatory environment is the most aggressive on the site and enforcement is real. the meta-analyses in athletes show modest body-comp shifts without consistent strength gains.

if you came in for pediatric GHD or adult GHD — these are the on-label indications with decades of outcome data. the 2022 KIMS registry strengthens the long-term safety case in true deficiency. weekly somatrogon is the most recent product win for patients who need GH and don't want a daily shot.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why S-tier

the original anabolic peptide drug. 40+ years of FDA approval across 11+ brand names for pediatric growth failure, adult GHD, HIV wasting, and short bowel syndrome. massive evidence base. criminalized for non-approved uses. one of the most regulated peptides in existence. four decades of pivotal trial evidence. S is the only defensible tier.

the core tension

the reference standard for 40 years. nothing has dethroned it. legally restricted for 30 of them. the gap between the literature and the gray market is enormous.

what it is

recombinant human growth hormone. 191 amino acids, identical to the GH the pituitary makes. genentech synthesized it in 1981, FDA approved Protropin in 1985. now sold under 11+ brand names: Genotropin, Humatrope, Norditropin, Nutropin, Omnitrope, Saizen, Serostim, Zomacton, Sogroya, Skytrofa, Ngenla. the last three are once-weekly formulations (2020, 2021, 2023).

what it does

binds the GH receptor on nearly every tissue. the main downstream signal is liver IGF-1, which drives anabolism, lipolysis, lean mass, bone turnover. in real GH deficiency the effect is clean and well-documented. in healthy adults at supraphysiologic doses, meta-analyses find modest body-composition shifts, unclear function, and common side effects.

origin

genentech cloned the human GH gene in 1981. Protropin landed at FDA in 1985 and ended the cadaver-GH era, which had been spreading Creutzfeldt-Jakob disease. Lilly, Novo, Pfizer, EMD Serono, Sandoz, Ferring, and Ascendis all launched competing formulations over the next four decades.

why researchers are interested

two parallel cultures. on-label: pediatric endocrinology and adult GHD, the foundational patient base. off-label: the anti-aging, longevity, and bodybuilding scene that grew out of Rudman's 1990 NEJM paper. twelve men over 60 with better body composition. the authors never claimed anti-aging. the clinics did anyway, for 35 years.

does it work

depends what you mean. for pediatric GHD, Turner syndrome, adult GHD, and HIV wasting, the evidence is overwhelming. the 2022 KIMS registry strengthens the long-term safety case in true deficiency. for anti-aging in healthy adults, Liu et al. 2007 (Annals of Internal Medicine) is the honest answer: small body-composition changes, unclear function, common side effects (carpal tunnel, edema, glucose intolerance). weekly somatrogon is a real win for the patients who need GH. anti-aging marketing is still ahead of the anti-aging evidence. the felony statute (21 U.S.C. § 333(e)) makes the off-label distribution side a separate conversation.

claims vs the data

• treats pediatric growth failure — supported — FDA-approved indication since 1985 across multiple trials. the original and uncontroversial use case.
• treats adult GH deficiency — supported — FDA-approved indication. well-established for pituitary disease and surgical/radiation-induced deficiency.
• reverses aging — contradicted — rudman 1990 NEJM paper has been widely misinterpreted. the authors explicitly did not claim this. follow-up studies have not confirmed anti-aging benefits.
• builds muscle mass — partially true — increases lean body mass and reduces fat mass at supra-physiologic doses. strength gains are debated, multiple meta-analyses find minimal functional improvement.
• safe long-term at anti-aging doses — contradicted — chronic exogenous GH elevates IGF-1, which is implicated in certain cancer risk pathways. long-term safety data in healthy adults is limited and concerning.
• over-the-counter HGH products work — contradicted — oral HGH is destroyed by digestion. OTC sprays, pills, and releasers do not reliably deliver GH. many contain no HGH at all.
• identical to natural GH — partially true — recombinant somatropin has the identical 191 aa sequence to endogenous human GH. pharmacokinetically different, natural GH pulses, recombinant is administered as a bolus.

key facts

• molecular formula: C₉₉₀H₁₄₆₄N₂₄₆O₂₈₄S₇
• molecular weight: 22,124 Da (191 aa)
• amino acids: 191
• half-life: ~2-4 hours (rapid-acting); ~1 week (long-acting variants)
• type: recombinant human growth hormone (somatropin)
• CAS: 12629-01-5
• 11+ FDA-approved brands
• 1985 first recombinant approval
• $7.7B global market 2025
• 21 USC 333(e) 5-year distribution statute

frequently asked questions

What is HGH?

Human growth hormone (somatropin) is a recombinant 191-amino-acid peptide hormone identical to endogenous GH produced by the pituitary gland. Multiple branded formulations are FDA-approved for specific deficiency and growth-related indications.

What does HGH do?

HGH stimulates linear growth in children with GH deficiency, increases lean body mass, reduces fat mass, and supports tissue repair and metabolism via IGF-1 mediated signaling. Clinical trials in approved indications show substantial efficacy; anti-aging claims in healthy adults have significantly weaker evidence.

How is HGH typically administered?

HGH is administered as subcutaneous injection, usually daily for standard somatropin or once weekly for long-acting formulations. FDA-approved dosing depends on indication, body weight, formulation, and IGF-1 response.

What are the side effects of HGH?

Common side effects include fluid retention, joint pain, carpal tunnel syndrome, and insulin resistance. Long-term supraphysiological use carries acromegaly-like risks including organ growth and potential cancer-risk elevation consistent with sustained IGF-1 elevation.

Is HGH FDA approved?

Yes. Multiple somatropin formulations (Humatrope, Genotropin, Norditropin, Omnitrope, Saizen, and others) are FDA-approved for specific indications including pediatric GH deficiency, adult GH deficiency, Turner syndrome, short stature conditions, and HIV-wasting. General anti-aging use is not FDA-approved.

How much does HGH cost?

Branded somatropin pricing varies widely by dose, brand, indication, insurance, and specialty-pharmacy channel. Gray-market somatropin pricing is a different market entirely. Anti-aging and performance distribution sits outside the FDA-approved indication frame and carries a stricter U.S. legal risk profile than most peptides on this site.

related peptides

• sermorelin — stimulates your own GH instead
• cjc-1295 — longer-acting GHRH analog, same goal
• tesamorelin — FDA-approved GHRH analog (HIV only)
• ipamorelin — GHRP that pulses GH release

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.